P53: an ubiquitous target of anticancer drugs (Q34539978)

2 August 2017

1 reference

title

P53: an ubiquitous target of anticancer drugs (English)

1 reference

2 August 2017

1

Mikhail V Blagosklonny

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

International Journal of Cancer

2 August 2017

published in

1 reference

2 August 2017

volume

98

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

161-166

1 reference

2 August 2017

cites work

Surfing the p53 network

1 reference

21 January 2018

1 reference

21 January 2018

1 reference

Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death?

21 January 2018

1 reference

MDM2--arbiter of p53's destruction

21 January 2018

1 reference

Regulation of the p53 tumor suppressor protein

21 January 2018

1 reference

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

Regulation of p53 stability by Mdm2

21 January 2018

1 reference

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

21 January 2018

1 reference

Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions

21 January 2018

1 reference

DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways

21 January 2018

1 reference

Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study

21 January 2018

1 reference

The complexity of p53 modulation: emerging patterns from divergent signals

21 January 2018

1 reference

DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation

21 January 2018

1 reference

Regulation of p53 function and stability by phosphorylation

21 January 2018

1 reference

Loss of function and p53 protein stabilization

21 January 2018

1 reference

Keeping an old friend under control: regulation of p53 stability

21 January 2018

1 reference

RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.

21 January 2018

1 reference

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.

21 January 2018

1 reference

Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation

21 January 2018

1 reference

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

21 January 2018

1 reference

Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6

21 January 2018

1 reference

Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B.

21 January 2018

1 reference

Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status.

21 January 2018

1 reference

Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha

21 January 2018

1 reference

Repression of BRCA1 through a feedback loop involving p53.

21 January 2018

1 reference

Proteasome inhibition: a new strategy in cancer treatment

21 January 2018

1 reference

Proteasome-dependent regulation of p21WAF1/CIP1 expression

21 January 2018

1 reference

p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts

21 January 2018

1 reference

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

21 January 2018

1 reference

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability

21 January 2018

1 reference

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo

21 January 2018

1 reference

Apoptosis induction resulting from proteasome inhibition

21 January 2018

1 reference

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

21 January 2018

1 reference

Molecular effects of paclitaxel: myths and reality (a critical review).

21 January 2018

1 reference

Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity

21 January 2018

1 reference

Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells

21 January 2018

1 reference

In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug

21 January 2018

1 reference

Tumor suppressor gene therapy for cancer: from the bench to the clinic.

21 January 2018

1 reference

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

21 January 2018

1 reference

Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity

21 January 2018

1 reference

Geldanamycin prevents nuclear translocation of mutant p53.

21 January 2018

1 reference

'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain

21 January 2018

1 reference

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

21 January 2018

1 reference

Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.

21 January 2018

1 reference

Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay

21 January 2018

1 reference

The role of the E6-p53 interaction in the molecular pathogenesis of HPV.

21 January 2018

1 reference

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53

21 January 2018

1 reference

Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage

21 January 2018

1 reference

Selective down-regulation of human papillomavirus transcription by 2-deoxyglucose

21 January 2018

1 reference

Activation of p53 in cervical carcinoma cells by small molecules.

21 January 2018

1 reference

Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein

21 January 2018

1 reference

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

Different impact of p53 and p21 on the radiation response of mouse tissues

21 January 2018

1 reference

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

21 January 2018

1 reference

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

21 January 2018

1 reference

Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs

21 January 2018

1 reference

Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1

21 January 2018

1 reference

The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest

21 January 2018

1 reference

Virus-mediated killing of cells that lack p53 activity

21 January 2018

1 reference

Achilles' heel of cancer?

21 January 2018

1 reference

Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs

21 January 2018

1 reference

Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation

21 January 2018

1 reference

Inhibition of RNA polymerase II as a trigger for the p53 response

21 January 2018

1 reference

Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop

21 January 2018

1 reference

21 January 2018

The ins and outs of p53

1 reference

MDM2-dependent ubiquitination of nuclear and cytoplasmic P53

21 January 2018

1 reference

p53-dependent induction of apoptosis by proteasome inhibitors

21 January 2018

1 reference

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

21 January 2018

1 reference

p53 is associated with cellular microtubules and is transported to the nucleus by dynein

21 January 2018

1 reference

The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association

21 January 2018

1 reference

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

21 January 2018

1 reference

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

21 January 2018

1 reference

Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells

21 January 2018

1 reference

Pharmacological rescue of mutant p53 conformation and function

21 January 2018

1 reference

Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.10158

1 reference

2 August 2017

1 reference